Kinnate lays off 70% of staff, pulls back from programs to save cash after data disappointment

Kinnate Biopharma is cutting deep. Months after its delayed cancer data disappointed investors, the biotech has revealed it is laying off 70% of its staff and narrowing its pipeline to stretch its cash reserves into the second quarter of 2026.